Jan Alenfall holds a PhD and has over twenty years’ experience from pharmaceutical research and development, for example from research regarding new treatment for immunological diseases and cancer. Alenfall was Head of Preclinical and Clinical Development at Bioglan. He has also been Head of Research at Probi AB. Alenfall has solid experience within research, product development, preclinical and clinical trials and also in commercial collaborations and in 2006 he was appointed CEO at DermaGen AB. Alenfall has been the author and co-author of 17 publications in scientific journals and has six patent applications.